Article
Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.
The lancet. Gastroenterology & hepatology - 1 Sept 2016
Waked Imam, Shiha Gamal, Qaqish Roula B, Esmat Gamal, Yosry Ayman, Hassany Mohamed, Soliman Reham, Mohey Mohammad A, Allam Naglaa, Zayed Naglaa, Asselah Tarik, Hall Coleen, Redman Rebecca, Mobashery Niloufar, Doss Wahid
Abstract excerpt
BACKGROUND: In Egypt, chronic hepatitis C virus (HCV) infection occurs in around 10% of the population (about 8 million individuals), and is a leading cause of liver cirrhosis, hepatocellular carcinoma, and mortality. Although HCV genotype 4 constitutes about 20% of HCV infections worldwide, the prevalence in Egypt is more than 90%. We assessed the efficacy and safety of the two direct-acting antiviral drugs...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.